Navigation Links
First Coronary Stent on Drug Eluting Balloon Implanted
Date:5/25/2010

HELMOND, The Netherlands, May 25, 2010 /PRNewswire/ -- Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

PIONEER, as part of Blue Medical's clinical program, is the trial that enables for the first time the delivery of a coronary stent that is mounted on a Drug Eluting Balloon. On placement of the stent a predetermined load of Paclitaxel is delivered to the vessel wall to support the vessel in adapting to the stent and reducing adverse effects in the first days after implantation.

The team of investigator Dr. Jacques Koolen enrolled the first patient in the Catharina Hospital Eindhoven. This will soon be followed by enrollment in five additional centers in the Netherlands under guidance of the Principal Investigator, Dr. Peter Smits of Maasstad Hospital Rotterdam.

The Drug Eluting Balloon product in the PIONEER trial delivers drugs at the stent placement only, instead of continous drug delivery by drug eluting stents. This reduces the period that medication is needed, which means total procedure costs are reduced significantly. The new procedure improves a patient's comfort, as the period for which he has to take daily antiplatelet medication is reduced from up to two years to one month.

A coronary balloon angioplasty is a minimally invasive procedure performed to improve blood flow to the heart muscle. In an angioplasty procedure a balloon is inflated to open the coronary artery. In addition, a small wire mesh tube, called a stent, may be permanently placed
'/>"/>

SOURCE Blue Medical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ExpertRECALL Awards First Scholarships for Product-Safety Education
2. China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results
3. Physicians Cite Positive First Clinical Experience with Volcanos Eagle Eye® Platinum Digital IVUS Catheter
4. In a World First, Asda Announces Not for Profit Price on All Cancer Treatment Drugs
5. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
6. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
7. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
8. China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010
9. Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference
10. China Sky One Medical Announces First Quarter 2010 Results
11. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Omnicell, Inc. (Nasdaq: OMCL ) a leading ... they will present at the UBS 21st Annual Global Healthcare ... Omnicell Speakers: Rob Seim, vice president ... DevelopmentDate: Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: ...
... LLC , ( www.curemark.com ), a drug research and ... recently hosted New York Senator Kirsten Gillibrand as she ... creation, locally and nationally.  Speaking at Curemark, which is ... proposal to expand, simplify and make permanent the Research ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Curemark Hosts New York Senator Kirsten Gillibrand 2Curemark Hosts New York Senator Kirsten Gillibrand 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... 19 The National Retail,Federation welcomed last night,s ... a House subcommittee to adopt the Senate,s version,when ... today. "The Senate bill is a strong ... while balancing the interests of employers," said NRF ...
... to treatments for diseases such as diabetes and Alzheimer,s , ... successfully reprogrammed adult stem cells from the testes of male ... blood vessels, contractile cardiac tissue, and brain cells. , If ... from humans, they may offer a source of new therapies ...
... plentiful this year, but inoculation rates are low, officials ... many Americans aren,t getting vaccinated for the flu, including ... workers -- U.S. health officials warned Wednesday. , "Despite ... still failing to protect a large proportion of people," ...
... accessed and plentiful, adult stem cells found in a male ... range of tissue types to help him fight disease -- ... , That,s the promise of a breakthrough study in mice ... New York City, who report their findings in the September ...
... International,( http://www.activator.com ), pioneer in chiropractic instrument,manufacturing and ... alliance,with three leading chiropractic companies to create the ... doctors improve the level of,care they provide patients, ... "What,s new about the Activator Advantage seminars is ...
... WASHINGTON, Sept. 19 More Americans will,have access ... bipartisan legislation passed by the U.S. Senate. The,"Mental ... plans that offer,mental health benefits to provide parity ... limitations. (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ) ...
Cached Medicine News:Health News:Retailers Welcome Senate Passage of Mental Health Parity Bill, Urge House to Adopt Senate Version at Subcommittee Markup 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:More Americans Urged to Get Flu Shots 2Health News:More Americans Urged to Get Flu Shots 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nation's Chiropractic Care: Focus on the Patients 2
... The Burdick EK-10 single-channel,electrocardiograph ... touch membrane keypad. It ... make a quick and,accurate ... ergonomically,designed with a built ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: